- Applied StemCell and Cellipont Bioservices have entered a strategic collaboration to support the development and manufacturing of iPSC-derived cell therapies.
- The partnership integrates upstream cell engineering with CDMO-led process development, cGMP manufacturing, and regulatory support to streamline development timelines.
Applied StemCell, Inc. has announced a strategic collaboration with Cellipont Bioservices to support the development and contract manufacturing of induced pluripotent stem cell (iPSC)-derived therapies.
The partnership is designed to connect early-stage cell engineering and cell banking with later-stage process development, cGMP manufacturing, and regulatory support. By aligning these stages, the companies aim to reduce technical risk and support progression from early development through clinical and commercial-scale production.
Applied StemCell contributes its iPSC technology portfolio, including GMP iPSC lines supported by a U.S. FDA Master File, precision-engineered iPSCs enabled by its TARGATT™ technology, and both GMP and non-GMP cell banking services. These capabilities are intended to support consistent cell line generation and facilitate transfer into manufacturing environments.
Cellipont Bioservices, a CDMO focused on cell therapy, will provide process development, analytical development, contract manufacturing, and regulatory support. Its infrastructure and manufacturing platforms will be applied to enable scalable production of iPSC-derived therapies for clinical and commercial use.
“Bringing iPSC-derived therapies to patients requires not only innovative cell engineering, but also manufacturing processes that are robust, compliant, and scalable.”
Darren Head, chief executive officer of Cellipont Bioservices
